HCPLive Network

Tofacitinib Slows Joint Damage in Rheumatoid Arthritis

 
FRIDAY, Jan. 25 (HealthDay News) -- Tofacitinib slows the progression of joint damage and improves disease activity in patients with rheumatoid arthritis (RA), according to a study published online Jan. 24 in Arthritis & Rheumatism.

Desiree van der Heijde, M.D., Ph.D., from the Leiden University Medical Center in the Netherlands, and colleagues randomly assigned 797 patients with RA who did not respond to methotrexate to receive tofacitinib or placebo. Patients received 5 or 10 mg tofacitinib twice a day. Patients in the placebo group were switched to 5 or 10 mg tofacitinib after three months if they did not respond, and all remaining placebo patients were switched to tofacitinib after six months.

The researchers found that, at six months, the American College of Rheumatology 20 percent improvement criteria response rates were significantly higher for both tofacitinib groups compared to the placebo group (51.5 percent for 5 mg, 61.8 percent for 10 mg, and 25.3 percent for placebo). The tofacitinib groups had reduced progression of joint erosion and joint space narrowing and a greater percentage of patients with no radiographic progression.

"Data from this 12-month interim analysis demonstrate that tofacitinib inhibits progression of structural damage and improves RA disease activity in patients with RA on methotrexate," van der Heijde and colleagues conclude.

The study was funded by Pfizer; several authors disclosed financial ties to Pfizer.
 

Abstract
Full Text (subscription or payment may be required)


Copyright © 2013 HealthDay. All rights reserved.
 
 

Further Reading
The addition of tofacitinib to rheumatoid arthritis (RA) treatment regimens improves patient response to non-biologic disease-modifying antirheumatic drugs (DMARDs).
Regular consumption of dietary long-chain n-3 polyunsaturated fatty acids (PUFAs) in fish is associated with reduced risk of rheumatoid arthritis (RA) in women.
Patients with rheumatoid arthritis who respond to tumor necrosis factor inhibitors show changes in activity in pain-related areas of the brain before clinical signs of improvement are observed, according to a study published in the February issue of Arthritis & Rheumatism.
For patients with early rheumatoid arthritis, smoking status does not impact treatment response to early combination therapy or initial methotrexate treatment with step-up therapy, according to a study published in the December issue of Arthritis Care & Research.
RAPID-2 results show that certolizumab pegol plus methotrexate improves pain, physical function, and quality of life in patients with rheumatoid arthritis.
For patients with rheumatoid arthritis (RA), the median time to discontinuation of therapy is 25.1 months, with longer time to discontinuation noted for those receiving tumor necrosis factor inhibitors (TNFi's).
Results presented at the American College of Rheumatology/Association of Rheumatology Professionals 2012 annual meeting show that adalimumab and methotrexate are more effective than DMARDs and prednisone in achieving remission in patients with early rheumatoid arthritis or undifferentiated arthritis patients.
More Reading